Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial-Reference-Cited by-同舟云学术

Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial

Published:2021-05 Issue: Volume: Page:
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Altorki Nasser K,McGraw Timothy E,Borczuk Alain C,Saxena Ashish,Port Jeffrey L,Stiles Brendon M,Lee Benjamin E,Sanfilippo Nicholas J,Scheff Ronald J,Pua Bradley B,Gruden James F,Christos Paul J,Spinelli Cathy,Gakuria Joyce,Uppal Manik,Binder Bhavneet,Elemento Olivier,Ballman Karla V,Formenti Silvia C

Funder

AstraZeneca plc

Publisher

Elsevier BV

Subject

Oncology

Reference36 articles.

1. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

2. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

3. Immunotherapy in patients with early stage resectable nonsmall cell lung cancer;Ghysen;Curr Opin Oncol,2019

4. Neoadjuvant PD-1 blockade in resectable lung cancer;Forde;N Engl J Med,2018

5. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): interim analysis and biomarker data from a multicenter study (LCMC3);Kwiatkowski;J Clin Oncol,2019

Cited by 180 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of neoadjuvant immunotherapy protocols and cycles for non-small cell lung cancer: a systematic review and meta-analysis;Frontiers in Oncology;2024-01-16

2. Notable-HCC: A phase Ib trial of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with early stage resectable hepatocellular carcinoma;2024-01-09

3. Utility of Molecular Markers in Predicting Local Control Specific to Lung Cancer Spine Metastases Treated with Stereotactic Body Radiotherapy;2024-01-09

4. Perioperative immunotherapy for resectable non-small-cell lung cancer;Clinical Cancer Bulletin;2024-01-08

5. The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC;Radiotherapy and Oncology;2024-01